CEVEC licenses CAP®Go technology in the field of veterinary vaccines
- Further step to establish CAP®Go as the production standard for difficult to express recombinant proteins
- First use of CAP®Go in the field of veterinary vaccines
- CEVEC grants license for the development, production and commercialization of veterinary vaccines based on CAP®Go technology
Cologne, Germany, July 06, 2017
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed a non-exclusive license agreement with a leading European veterinary pharmaceutical company for use of its proprietary CAP®Go cells in the development, production and commercialization of two difficult to express recombinant proteins in the field of veterinary vaccines.